Gain Therapeutics (GANX) Free Cash Flow (2020 - 2026)
Gain Therapeutics (GANX) posted quarterly Free Cash Flow of -$4.7 million for Q1 2026, down 23.76% year-over-year from -$6.2 million in Q1 2025, and down 2.39% quarter-over-quarter from -$4.6 million in Q4 2025.
Gain Therapeutics (GANX) Free Cash Flow (2020 - 2026) Analysis & Trends
Gain Therapeutics' Free Cash Flow history runs 7 years deep, the most recent figure standing at -$4.7 million for Q1 2026.
- In Q1 2026, Free Cash Flow fell 23.76% year-over-year to -$4.7 million; the TTM figure through Mar 2026 stood at -$19.4 million (down 1.28% YoY), while the FY2025 annual figure was -$18.5 million, up 2.29% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$4.7 million, down from -$4.6 million in the prior quarter.
- The five-year high for Free Cash Flow was -$2.5 million in Q1 2022, with the low at -$6.1 million in Q3 2024.
- The 5-year median for Free Cash Flow is -$4.6 million (2025), against an average of -$4.5 million.
- The sharpest annual moves came in 2023 and 2024: Free Cash Flow sank 72.22% in 2023, then surged 38.98% in 2024.
- Gain Therapeutics' Free Cash Flow stood at -$4.1 million in 2022, then sank by 39.42% to -$5.7 million in 2023, then soared by 38.98% to -$3.5 million in 2024, then plunged by 33.7% to -$4.6 million in 2025, then retreated by 2.39% to -$4.7 million in 2026.
- Business Quant data shows GANX's Free Cash Flow at -$4.7 million in Q1 2026, -$4.6 million in Q4 2025, and -$4.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Gain Therapeutics | 85.97 Mn | 85.97 Mn | - | -4.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.67 Mn |
| Jun 30, 2026 | -4.67 Mn |
| Mar 31, 2026 | -4.73 Mn |
| Mar 31, 2026 | -4.73 Mn |
| Dec 31, 2025 | -4.62 Mn |
| Dec 31, 2025 | -4.62 Mn |
| Sep 30, 2025 | -4.93 Mn |
| Sep 30, 2025 | -4.93 Mn |
| Jun 30, 2025 | -5.10 Mn |
| Jun 30, 2025 | -5.10 Mn |
| Mar 31, 2025 | -3.82 Mn |
| Mar 31, 2025 | -3.82 Mn |
| Dec 31, 2024 | -3.45 Mn |
| Dec 31, 2024 | -3.45 Mn |
| Sep 30, 2024 | -6.09 Mn |
| Sep 30, 2024 | -6.09 Mn |
| Jun 30, 2024 | -5.76 Mn |
| Jun 30, 2024 | -5.76 Mn |
| Mar 31, 2024 | -3.59 Mn |
| Mar 31, 2024 | -3.59 Mn |